Connect with us

Press Releases

Zoetis Announces U.S. Launch of Alphatrak 3 Glucose Monitoring System for Cats and Dogs

System allows for seamless data sharing and communication via the mobile app.




(PRESS RELEASE) PARSIPPANY, NJ – Zoetis, a global leader in pet care, announced the United States launch of the AlphaTrak 3 blood glucose monitoring system for cats and dogs living with diabetes. Building on the AlphaTrak legacy as the #1 veterinarian recommended brand for in-clinic glucose monitoring, AlphaTrak 3 features a new mobile app that enables data collection, storage and sharing between pet owners and veterinary healthcare teams. The AlphaTrak 3 blood glucose monitoring system allows for seamless data sharing and communication via the mobile app, making it easier to share a pet’s glucose data and other vital information with the veterinary practice in real-time, and offering veterinarians and pet owners greater confidence in diabetic pet care.

Prevalence of Diabetes in Pets

The prevalence of diabetes in dogs increased 79% from 2006 to 2016, while the prevalence in cats increased 18%. Additionally, diabetes is nearly three times more common in cats than it is in dogs.2

“Diabetes is becoming more common in dogs and cats over time,” said Georgette D. Wilson, DVM, Senior Manager and Global Diagnostics Platform Medical Lead at Zoetis. “Though a diabetes diagnosis may be overwhelming for pet owners, the disease can be successfully managed. The new, innovative AlphaTrak 3 blood glucose monitoring system provides veterinarians with accurate data that allows them to confidently implement optimal medical treatment.3 Pet owners can also rest easy knowing that they are providing the best possible care to their pets for years to come.”

Key Technology Features

AlphaTrak 3 is calibrated specifically for dogs and cats and provides reliable data in as little as five seconds, which is faster than the AlphaTrak 2 blood glucose monitoring system currently available. AlphaTrak 3 requires a small sample volume of 0.3 microliters and provides a blood glucose dynamic range of 20-750 milligrams per deciliter. The new AlphaTrak 3 mobile app allows for better data capture from pet owners compared to previous systems, including their pet’s eating, drinking, exercise and time of insulin, and provides the ability to track glucose trends that can be used to inform care decisions with their veterinarians.


For veterinary clinics using VETSCAN FUSE technology, AlphaTrak 3 easily integrates with a pet’s medical records, helping pet owners partner with their veterinarians to better co-manage their pet’s health and drive more informed decision-making and improved medical outcomes.

Transition From AlphaTrak 2 to AlphaTrak 3 Blood Glucose Monitoring System

AlphaTrak 3 starter kits and devices is now available for purchase. AlphaTrak 2 testing strips are not compatible with AlphaTrak 3 devices. Zoetis will continue to sell AlphaTrak 2 testing strips for use with the AlphaTrak 2 through September 2023.

For more information, please visit

About AlphaTrak 3

AlphaTrak 3 is an easy-to-use veterinary canine and feline blood glucose monitoring system used to monitor the blood sugar of cats and dogs with diabetes. Dogs and cats diagnosed with diabetes often require regular glucose testing to manage their health. Use of the AlphaTrak 3 blood glucose monitoring system in clinic helps veterinarians make more informed decisions about their patients’ medical care, while allowing pet owners to accurately monitor their pet’s blood glucose at home, with accurate results in a few easy steps.3

About Zoetis

As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After nearly 70 years innovating ways to predict, prevent, detect, and treat animal illness, Zoetis continues to stand by those raising and caring for animals worldwide – from livestock farmers to veterinarians and pet owners. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $7.8 billion in 2021 with approximately 12,100 employees. For more information, visit




Sponsored by Cogent Solutions Group

Reduce Your Pet’s Hip & Joint Discomfort with the Most Researched Hyaluronan on the Market

Nearly 60% of dogs and 90% of cats suffer from joint discomfort. Trixsyn joint supplement contains a patented and proven hyaluronic acid molecule for maximum efficacy to promote joint, bone, soft tissue, and cartilage health, keeping your pet feeling comfortable, for longer. Trixsyn is veterinarian recommended, safe and all-natural, and contains research-proven ingredients. Get your paws on the most-researched hyaluronic acid on the market. Learn more at

Promoted Headlines

Most Popular